Drug Trial Radar · NCT00001082
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
Last checked: Nov 19, 2026Latest source record: Oct 1, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
505
Actual
Start
Dec 1996
Primary completion
Jan 1999
Study completion Aug 1999
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of adefovir dipivoxil in prolonging survival of patients with advanced HIV disease. In CMV prophylaxis substudy: To evaluate the efficacy of adefovir dipivoxil in preventing the development of CMV end-organ disease in patients with advanced HIV coinfected with CMV. The optimal treatment for HIV infection and the prevention of CMV disease has not been identified. Currently available antiretroviral therapies are hampered by both significant toxicities and the development of resistance. In addition, agents for preventing CMV disease, such as oral ganciclovir, are complicated by poor bioavailability and decreased compliance secondary to toxicities. Moreover, discordant results have been reported regarding the effectiveness of oral ganciclovir for preventing CMV disease. There is a need for newer agents with anti-HIV and anti-herpesvirus activity that have good pharmacokinetic and safety profiles and that will be well tolerated by patients. Adefovir dipivoxil is an oral pro-drug of PMEA, a nucleoside analog with activity against a broad spectrum of retroviruses and herpesviruses, including important human pathogens, such as HIV-1, HIV-2 and CMV. Due to its anti-HIV and anti-herpesvirus activity, adefovir dipivoxil may be able to decrease the incidence of opportunistic herpesvirus infections and prolong survival in patients with advanced HIV infection.
Conditions
- Cytomegalovirus Infections
- HIV Infections
Interventions
LevocarnitineDrug
500 mg tablet taken orally daily
Adefovir dipivoxilDrug
120 mg tablet taken orally daily
Adefovir dipivoxil placeboDrug
Oral placebo tablet taken daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- MorbidityTime frame: Throughout study
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Community Consortium / UCSF
San Francisco, California
Denver CPCRA / Denver Public Hlth
Denver, Colorado
Washington Reg AIDS Prog / Dept of Infect Dis
Washington D.C., District of Columbia
AIDS Research Consortium of Atlanta
Atlanta, Georgia
AIDS Research Alliance - Chicago
Chicago, Illinois
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
New Orleans, Louisiana
Wayne State Univ - WSU/DMC / Univ Hlth Ctr
Detroit, Michigan
Henry Ford Hosp
Detroit, Michigan
Southern New Jersey AIDS Cln Trials / Dept of Med
Camden, New Jersey
North Jersey Community Research Initiative
Newark, New Jersey
Partners in Research / New Mexico
Albuquerque, New Mexico
Harlem AIDS Treatment Grp / Harlem Hosp Ctr
New York, New York
The Research and Education Group
Portland, Oregon
Philadelphia FIGHT
Philadelphia, Pennsylvania
Richmond AIDS Consortium / Div of Infect Diseases
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.